Ascidian and Lilly Enter Global Research Collaboration to Develop RNA Exon Editors for Devastating Kidney Diseases
Combines Ascidian's RNA exon editing product engine with Lilly's leadership in genetic medicines Programs target undisclosed inherited kidney diseases, with Lilly option to expand to additional targets BOSTON, June 3, 2026 /PRNewswire/ -- Ascidian Therapeutics, a biotechnology company...
Combines Ascidian's RNA exon editing product engine with Lilly's leadership in genetic medicines Programs target undisclosed inherited kidney diseases, with Lilly option to expand to additional targets BOSTON, June 3, 2026 /PRNewswire/ -- Ascidian Therapeutics, a biotechnology company...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.